Ensifentrine for the Treatment of Chronic Obstructive Pulmonary Disease

Questions for Deliberation and Voting: June 14, 2024 Public Meeting

These questions are intended for the deliberation of the Midwest CEPAC voting body at the public meeting.

Patient Population for all questions: Adults with Moderate to Severe COPD.

Clinical Evidence

1. Is the current evidence adequate to demonstrate that the net health benefit of ensifentrine added to maintenance therapy is superior to that of maintenance therapy alone?
   Yes         No

Benefits Beyond Health and Special Ethical Priorities

To help inform judgments of overall long-term value for money, please indicate your level of agreement with the following statements:

1=Strongly Disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree

2. There is substantial unmet need despite currently available treatments.
3. This condition is of substantial relevance for people from a racial/ethnic group that have not been equitably served by the healthcare system.

To help inform judgments of overall long-term value for money, please indicate your level of agreement with the following statements based on the relative effects of ensifentrine added to maintenance therapy versus maintenance therapy alone:

1=Strongly Disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree

4. The treatment is likely to produce substantial improvement in caregivers’ quality of life and/or ability to pursue their own education, work, and family life.
5. The treatment offers a substantial opportunity to improve access to effective treatment by means of its mechanism of action or method of delivery.
6. Other: as determined pre-meeting by ICER team based on input from patients, clinical experts, and appraisal committee members.
Long-Term Value for Money

7. Given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering benefits beyond health and special ethical priorities, what is the long-term value for money of ensifentrine added to maintenance therapy compared to maintenance therapy alone at assumed pricing?*
   a. High long-term value for money at assumed pricing
   b. Intermediate long-term value for money at assumed pricing
   c. Low long-term value for money at assumed pricing

*This vote will only be taken if a price becomes available for ensifentrine.